Idazoxan

Idazoxan
Systematic (IUPAC) name
	(±)-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole
Clinical data
Legal status	Uncontrolled;
Routes of; administration	Oral
Identifiers
CAS Number	79944-58-4
ATC code	none
PubChem	CID: 54459
ChemSpider	49184
UNII	Y310PA316B
ChEMBL	CHEMBL10316
Chemical data
Formula	C11H12N2O2
Molecular mass	204.225 g/mol
	SMILES C1CN=C(N1)C2COC3=CC=CC=C3O2 ;
	InChI InChI=1S/C11H12N2O2/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,10H,5-7H2,(H,12,13) ; Key:HPMRFMKYPGXPEP-UHFFFAOYSA-N ;
(what is this?) (verify)

Idazoxan (INN) is a drug which is used in scientific research. It acts as both a selective α2 adrenergic receptor antagonist, and an antagonist for the imidazoline receptor.^[1]^[2] Idazoxan has been under investigation as an antidepressant, but it did not reach the market as such. More recently, it is under investigation as an adjunctive treatment in schizophrenia. Due to its alpha-2 receptor antagonism it is capable of enhancing therapeutic effects of antipsychotics, possibly by enhancing dopamine neurotransmission in the prefrontal cortex of the brain, a brain area thought to be involved in the pathogenesis of schizophrenia.

References